Vtv Theraptcs Cl A (VTVT)

$37.28 +1.28 (3.56%)
Market Cap 141.78M
Revenue (ttm) 0.00
Net Income (ttm) -26.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 41,500
Avg Vol 40,808
Day's Range N/A - N/A
Shares Out 3.94M
Stochastic %K 74%
Beta 0.44
Analysts Strong Sell
Price Target $53.33

Company Profile

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a lic...

Industry: Biotechnology
Sector: Healthcare
Phone: 336 841 0300
Fax: 336 841 0310
Address:
3980 Premier Drive, Suite 310, High Point, United States
SuperGreenToday
SuperGreenToday Mar. 23 at 8:38 PM
$VTVT
0 · Reply
GDS_investing
GDS_investing Mar. 23 at 5:45 PM
$VTVT It's quiet here today. $ZIM $RFL $AGEN $BHC
0 · Reply
GDS_investing
GDS_investing Mar. 23 at 4:19 PM
$VTVT Day by day the stock price is converging we are close to a breakout be patient it will come soon 44$ is the key ! fast target 56 and 84 ! LONG and STRONG $VTVT watch $PTLE $DJT $SMCI
1 · Reply
LongBallBarn
LongBallBarn Mar. 23 at 3:44 PM
$VTVT $AIFF $ORIS
0 · Reply
dcajic2
dcajic2 Mar. 23 at 3:29 PM
$VTVT Looking good.
0 · Reply
GDS_investing
GDS_investing Mar. 23 at 12:44 PM
$VTVT today vTv Therapeutics to Participate in the 38th Annual ROTH Conference https://finance.yahoo.com/news/vtv-therapeutics-participate-38th-annual-120000202.html
0 · Reply
GDS_investing
GDS_investing Mar. 20 at 3:17 PM
$VTVT Quiet today.
0 · Reply
dcajic2
dcajic2 Mar. 19 at 5:03 PM
$VTVT Will add every week until summer
0 · Reply
GDS_investing
GDS_investing Mar. 17 at 4:25 PM
$VTVT Day by day the stock price is converging we are close to a breakout be patient it will come soon 44$ is the key ! fast target 56 and 84 ! LONG and STRONG $VTVT watch $AGEN $BW $NVDA
0 · Reply
dcajic2
dcajic2 Mar. 17 at 2:57 PM
$VTVT slowly adding. Should get some news second half of the year.
0 · Reply
Latest News on VTVT
vTv Therapeutics to Participate in the 38th Annual ROTH Conference

Mar 16, 2026, 8:00 AM EDT - 7 days ago

vTv Therapeutics to Participate in the 38th Annual ROTH Conference

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 10, 2026, 4:01 PM EDT - 13 days ago

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst

Feb 28, 2026, 5:11 AM EST - 24 days ago

VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst

vTv Therapeutics to Participate in Upcoming Investor Conferences

Feb 13, 2026, 8:00 AM EST - 5 weeks ago

vTv Therapeutics to Participate in Upcoming Investor Conferences

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

Feb 2, 2026, 8:00 AM EST - 7 weeks ago

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

Dec 18, 2025, 4:05 PM EST - 3 months ago

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 4:15 PM EST - 4 months ago

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

Oct 9, 2025, 8:00 AM EDT - 5 months ago

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

Sep 15, 2025, 8:00 AM EDT - 6 months ago

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 4:57 PM EDT - 7 months ago

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 7 months ago

vTv Therapeutics to Participate in Upcoming September Investor Conferences

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Sep 2, 2025, 8:00 AM EDT - 7 months ago

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:15 PM EDT - 7 months ago

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Aug 11, 2025, 8:00 AM EDT - 8 months ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Aug 7, 2025, 8:00 AM EDT - 8 months ago

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

Jun 11, 2025, 8:00 AM EDT - 10 months ago

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 19, 2025, 9:00 AM EDT - 11 months ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025, 4:01 PM EDT - 11 months ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

May 15, 2025, 12:00 PM EDT - 11 months ago

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 20, 2025, 5:35 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges

Mar 17, 2025, 1:59 PM EDT - 1 year ago

FDA Lifts Clinical Hold On vTv Therapeutics' Phase 3 Diabetes Trial, Stock Surges

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Mar 17, 2025, 8:30 AM EDT - 1 year ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 9, 2024, 7:33 AM EST - 1 year ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Dec 2, 2024, 4:05 PM EST - 1 year ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Aug 8, 2024, 4:15 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jul 26, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

Jun 24, 2024, 4:05 PM EDT - 1 year ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 28, 2024, 8:00 AM EDT - 1 year ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

May 9, 2024, 4:51 PM EDT - 2 years ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 19, 2024, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 13, 2024, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 4, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Mar 1, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 28, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Feb 22, 2024, 4:00 PM EST - 2 years ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 9, 2023, 4:30 PM EST - 2 years ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 8, 2023, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 2, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Nov 1, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

Sep 27, 2023, 8:30 AM EDT - 2 years ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 26, 2023, 8:30 AM EDT - 2 years ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Sep 18, 2023, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 11, 2023, 4:30 PM EDT - 2 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Aug 10, 2023, 8:33 AM EDT - 2 years ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 16, 2023, 8:00 AM EDT - 3 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

Jun 15, 2023, 7:33 AM EDT - 3 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 24, 2023, 9:00 AM EDT - 3 years ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

May 11, 2023, 4:15 PM EDT - 3 years ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

Apr 20, 2023, 8:00 AM EDT - 3 years ago

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 6, 2023, 5:56 PM EST - 3 years ago

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

SuperGreenToday
SuperGreenToday Mar. 23 at 8:38 PM
$VTVT
0 · Reply
GDS_investing
GDS_investing Mar. 23 at 5:45 PM
$VTVT It's quiet here today. $ZIM $RFL $AGEN $BHC
0 · Reply
GDS_investing
GDS_investing Mar. 23 at 4:19 PM
$VTVT Day by day the stock price is converging we are close to a breakout be patient it will come soon 44$ is the key ! fast target 56 and 84 ! LONG and STRONG $VTVT watch $PTLE $DJT $SMCI
1 · Reply
LongBallBarn
LongBallBarn Mar. 23 at 3:44 PM
$VTVT $AIFF $ORIS
0 · Reply
dcajic2
dcajic2 Mar. 23 at 3:29 PM
$VTVT Looking good.
0 · Reply
GDS_investing
GDS_investing Mar. 23 at 12:44 PM
$VTVT today vTv Therapeutics to Participate in the 38th Annual ROTH Conference https://finance.yahoo.com/news/vtv-therapeutics-participate-38th-annual-120000202.html
0 · Reply
GDS_investing
GDS_investing Mar. 20 at 3:17 PM
$VTVT Quiet today.
0 · Reply
dcajic2
dcajic2 Mar. 19 at 5:03 PM
$VTVT Will add every week until summer
0 · Reply
GDS_investing
GDS_investing Mar. 17 at 4:25 PM
$VTVT Day by day the stock price is converging we are close to a breakout be patient it will come soon 44$ is the key ! fast target 56 and 84 ! LONG and STRONG $VTVT watch $AGEN $BW $NVDA
0 · Reply
dcajic2
dcajic2 Mar. 17 at 2:57 PM
$VTVT slowly adding. Should get some news second half of the year.
0 · Reply
GDS_investing
GDS_investing Mar. 17 at 2:47 PM
$VTVT Latest recommendations for VTVT STRONG BUY PRICE TARGET 67$ ! LONG watch $BIAF
1 · Reply
GDS_investing
GDS_investing Mar. 16 at 8:19 PM
$VTVT good day for $VTVT long
0 · Reply
dcajic2
dcajic2 Mar. 16 at 6:02 PM
$VTVT Added. Maybe just maybe this is going to $50 in the next few months.
0 · Reply
JimJames
JimJames Mar. 16 at 4:07 PM
$VTVT I feel very soon we will pass through that resistance at $43
0 · Reply
JimJames
JimJames Mar. 13 at 6:43 PM
$VTVT red to green on better volume
0 · Reply
dcajic2
dcajic2 Mar. 13 at 4:23 PM
$VTVT Under $30 was the right call. Started a long position too early. No real news coming until summer
0 · Reply
GDS_investing
GDS_investing Mar. 13 at 3:36 PM
$VTVT same gift add more
0 · Reply
dcajic2
dcajic2 Mar. 12 at 7:47 PM
$VTVT volume is good. Where are the buyers coming from? No news
0 · Reply
GDS_investing
GDS_investing Mar. 12 at 7:30 PM
$INVZ told you sorry for you guys. come to $VTVT for long 44 56 84 ... 480 next year after gda
1 · Reply
km1663
km1663 Mar. 12 at 6:41 PM
$VTVT Not sure if everyone saw this. Its maybe concerning in the short term, but I'm not going anywhere, and if anything may give a chance to add a share or two. Always.... https://www.marketbeat.com/instant-alerts/vtv-therapeutics-nasdaqvtvt-share-price-crosses-below-50-day-moving-average-should-you-sell-2026-03-12/
0 · Reply
dcajic2
dcajic2 Mar. 12 at 6:26 PM
$VTVT Thinking added too soon. Good volume but stock continues to go lower. Under $30 will add more
0 · Reply
dcajic2
dcajic2 Mar. 12 at 3:50 PM
$VTVT long again. Volume has been good the last few days. Hopefully news will actually come soon with this company. Results of trials will not be available until second half of the year.
0 · Reply